Evidence map›Paper›PMID 33138155›Full record

ArticleMedicina (Kaunas, Lithuania)2020

Effects of the CB1 Receptor Antagonists AM6545 and AM4113 on Insulin Resistance in a High-Fructose High-Salt Rat Model of Metabolic Syndrome.

Basma G Eid, Thikryat Neamatallah, Abeer Hanafy, Hany M El-Bassossy, Hibah M Aldawsari, Kiran Vemuri, Alexandros Makriyannis

Open access · goldAbstract read
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. CB1 Cannabinoid Receptor Signaling and Biased Signaling.Molecules (Basel, Switzerland) · 2021
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Basma G EidDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Thikryat NeamatallahDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-2762-7108
Abeer HanafyDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Hany M El-BassossyDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
Hibah M AldawsariDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-9067-8565
Kiran VemuriCenter for Drug Discovery, Northeastern University, Boston, MA 02115, USA.
Alexandros MakriyannisCenter for Drug Discovery, Northeastern University, Boston, MA 02115, USA.
King Abdulaziz University · SANortheastern University · USKafrelsheikh University · EGZagazig University · EG

Funding

King Abdulaziz University No. 3-166-36-HiCi
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Insulin ResistanceMetabolic SyndromeAnimalsFructoseMaleMorpholinesPyrazolesRatsRats, WistarReceptor, Cannabinoid, CB1Uric AcidAM4113AM6545FructoseMorpholinesPyrazolesReceptor, Cannabinoid, CB1Uric AcidAM4113AM6545cannabinoidsinsulin resistancemetabolic syndrome

Identifiers

PMID33138155
PMCPMC7692885
OpenAlexW3094864969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.